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Abstract
Background—Human milk oligosaccharides (HMOs) shape the intestinal microbiota in term 
infants. In premature infants, alterations in the intestinal microbiota (dysbiosis) are associated with 
risk of necrotizing enterocolitis and sepsis and the influence of HMOs on the microbiota is 
unclear.
Methods—Milk, urine, and stool specimens from 14 mother-premature infant dyads were 
investigated by mass spectrometry for HMO composition. The stools were analyzed by next-
generation sequencing (NGS) to complement a previous analysis.
Results—Percentages of fucosylated and sialylated HMOs were highly variable between 
individuals but similar in urine, feces and milk within dyads. Differences in urine and fecal HMO 
composition suggest variability in absorption. Secretor status of the mother correlated with the 
urine and fecal content of specific HMO structures. Trends toward higher levels of Proteobacteria 
and lower levels of Firmicutes, were noted in premature infants of non-secretor mothers. Specific 
HMO structures in the milk, urine and feces were associated with alterations in fecal 
Proteobacteria and Firmicutes.
Conclusion—HMOs may influence the intestinal microbiota in premature infants. Specific 
HMOs, for example those associated with secretor mothers, may have a protective effect by 
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decreasing pathogens associated with sepsis and necrotizing enterocolitis while other HMOs may 
increase dysbiosis in this population.
Introduction
Human milk oligosaccharides (HMOs) are the third largest component of human milk. 
These complex carbohydrates are produced in a wide variety of structures that vary from 
woman to woman and within a given woman over time at great nutritional cost to the 
mother, and yet are not digestible by the infant(1). This observation prompts the obvious 
evolutionary question: what is the benefit to the mother-baby dyad of these structures? 
HMOs appear to have multiple functions. First, they shape the composition of the infant 
intestinal microbiota through selective consumption by commensal bacteria(2, 3). 
Bifidobacteria and Bacteroidetes become dominant intestinal bacteria in healthy breast-fed 
term infants due to their ability to digest and utilize HMOs via specific glycosidases, while 
most pathogenic Enterobacteriaceae lack these enzymes and are unable to utilize HMOs as a 
food source(4). Second, HMOs have structural homology to many cell surface glycans and 
thus act as decoys by binding to luminal bacteria that are then unable to bind to the surface 
of the enterocyte(5). Third, HMOs are absorbed into the vasculature(6) and excreted into the 
urine(7) potentially binding to and decreasing the capacity of invasive bacteria to cause 
sepsis and urinary tract infections(8). Fourth, sialic acid containing HMOs may be important 
in neurodevelopment(9).
Premature infants are at increased risk for necrotizing enterocolitis (NEC), sepsis, 
pneumonia, and neurodevelopmental delays due to immaturity and dysfunction of 
essentially every component of innate immunity. Premature infants who receive their 
mother’s own milk have lower rates of NEC and sepsis than those that receive formula(10). 
This is likely due to a variety of human milk components including immunoglobulins, 
lactoferrin, lysozyme and HMOs. Milk produced by women who deliver preterm differs 
from that of women delivering at term including the amounts and types of HMOs(11). 
Women delivering preterm have much wider variation (both between women and for a given 
woman over time) in the percentage of HMOs that contain fucose or sialic acid than women 
who deliver at term(12).
HMO structure is influenced in part by mutations in the maternal fucosyltransferase 2 
(FUT2) gene. Individuals who are homozygous for mutations in the FUT2 gene (historically 
referred to as “non-secretors”) are unable to produce α1,2 fucosylated glycans in their 
secretions including breast milk. Non-secretor individuals have lower levels of commensal 
bifidobacteria, are at decreased risk for infections with a variety of intestinal viruses, but 
have an increased risk for Crohn’s disease(13), celiac disease(14) and NEC(15). The 
influence of maternal secretor status on the infant microbiota has not been well 
characterized.
In this study, our objective was to determine the HMO composition of milk, urine, and feces 
from 14 premature infants receiving only human milk and their mothers and correlate these 
with the composition of the fecal microbiota. We hypothesized that ingested HMOs 
influence the intestinal microbiota.
Underwood et al. Page 2
Pediatr Res. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results
Relative abundances of the measured HMOs in milk, urine, and feces for all 14 dyads are 
summarized in Table 1 (the 4-digit labels correspond to the number of hexose, fucose, N-
acetylhexosamine, and sialic acid residues, in that order. For example, the label 4120 
(M=1220.47) means that there are 4 hexose, 1 fucose, and 2 N-acetylhexosamine residues in 
the structure). Representative mass spectra of milk from one of the mothers are presented in 
Supplemental Figures 1–3 (online) with a schematic diagram of HMO structure. The high 
degree of inter-individual variability is evident from the standard deviations in Table 1. Most 
dyads showed similarity in HMO groups across specimen type (ie milk composition was 
similar to fecal and urine composition). Figure 1 presents relative abundance of HMO 
groups for each dyad and Table 2 presents the combined data for all dyads. Total 
fucosylated, sialylated, fucosylated-sialylated, and non-fucosylated/non-sialylated HMOs 
were similar across specimen type (Supplemental Figure 4 (online)) and correlations 
between milk and fecal HMO groups were strong (Supplemental Figure 5 (online)). 
Individual HMOs however showed considerable heterogeneity. Structures relatively more 
abundant in feces than in urine included F-LSTc (p<0.01), LNFP II, 5130a, 5130c, and the 
group of 5 structures with mass 1731 (p<0.05) and TFLNH and 6’SL (p=0.05–0.1). We 
hypothesize that these HMOs are not significantly absorbed from the gut into the 
bloodstream. Several structures were not present in milk but found in either urine (3’Sle), 
feces (TFiLNO, 5330a), or both (A-hepta, 3’SLN). The origin of these structures is unclear; 
it is possible that these structures were present in earlier milk samples or that they were 
constructed or altered in the gut lumen by gut microbial enzymes. The only structure 
significantly more abundant in urine than feces was 3’Sle (p<0.01), though other structures 
showed a similar trend (3’SL, 3’SLN, LNFP I, LNFP V p=0.1–0.2). We hypothesize that 
these HMOS are absorbed from the gut into the bloodstream and filtered by the kidneys. The 
difference between 3’SL and 6’SL is striking as both structures have the same molecular 
weight with the difference in linkage apparently influencing absorption from the gut.
The secretor status of the mothers was predicted based on the percentages of 2’FL and 
LDFT (16). Of the 14 mothers enrolled 8 were secretors and 6 were non-secretors. Urine and 
fecal HMOs suggested a similar pattern in the infant to that of the mother’s milk in all but 
infant number 13 (Table 3). The fecal microbiota was analyzed by terminal restriction 
fragment length polymorphism (TRFLP) in the original study (17). Based on the TRFLP 
data of all 14 specimens, infants of secretor mothers had lower γ-Proteobacteria (p=0.046) 
and higher Lactobacillaceae (p=0.02). For the current study, a more robust approach using 
next-generation sequencing (NGS) was performed on the 12 fecal samples for which 
sufficient sample remained and is summarized in Figure 2 and Supplemental Figure 6 
(online). Note that the major HMO consuming orders of bacteria (Bifidobacteriales and 
Bacteroidales) are present in small numbers as has been previously demonstrated in 
premature infants. In this small sample, the differences by NGS in overall microbial 
composition between infants of secretor mothers and non-secretor mothers did not reach 
statistical significance, however the following trends were noted at the phylum level: 
increased Firmicutes (p=0.08) in the feces of infants of secretor mothers, and at the order 
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level decreased Enterobacteriales (phylum Proteobacteria, p=0.06) in the feces of infants of 
secretor mothers.
Correlations between HMOs in milk and fecal bacteria by NGS are presented at the phylum 
level in Figure 3 (HMO groups), Supplemental Figure 7 (online) (HMO groups, top panel) 
and Table 4 (individual HMOs). For many HMOs, the associations for the dominant phyla 
(Firmicutes and Proteobacteria) are in opposing directions. Figure 4 (top panel) summarizes 
correlations at the order level with the strongest correlations between HMOs in the milk and 
fecal Enterobacteriales (phylum Proteobacteria, positive correlation with HMOs containing 
neither fucose nor sialic acid and negative correlation with fucosylated HMOs) .
HMOs in the feces must traverse the length of the GI tract without being absorbed into the 
bloodstream or consumed by intestinal bacteria. In a pilot study of term breast-fed infants, as 
HMO consuming bacteria increased in the feces over time, fecal HMOs decreased in a 
structure specific manner (i.e. structures that are able to be consumed by the dominant 
bacteria decrease while those HMOs that are not digestible by the dominant bacteria persist)
(18). In these preterm infants, correlations are noted between groups of HMOs in the feces 
(Supplemental Figure 7 (online), bottom panel) and individual HMO structures (Table 5) and 
fecal bacterial composition at the phylum level. At the order level, the persistence of 
fucosylated HMOs in the feces shows a positive correlation with Pasteurellales, 
Pseudomonales, and Burkholderiales and a negative correlation with Enterobacteriales 
(Figure 4, bottom panel). A detailed heat map summarizing Spearman’s correlations for 
milk and fecal HMO groups and fecal bacteria at the genus level as determined by NGS in 
the current study is included as Supplemental Figure 8 (online). While the determination of 
absolute abundances of HMOs in the milk and feces is beyond the scope of this paper, 
previous studies have demonstrated that HMO content in feces is about 50% of that in 
milk(7).
HMOs in the urine have been absorbed from the GI tract and filtered by the kidneys. Table 6 
presents associations between urine HMOs and fecal bacteria as determined by NGS. Note 
that Tables 4–6 include only structures correlated with changes in fecal phylum with p 
values < 0.1, ie the structures not listed did not demonstrate significant correlations. While 
the determination of absolute abundances of HMOs in the urine is beyond the scope of this 
paper, previous studies have demonstrated that HMO content in urine is about 20% of that in 
milk(7).
Discussion
Bifidobacteria and Bacteroidetes are the dominant fecal bacteria and the primary consumers 
of HMOs in healthy breast-fed term infants, but are generally rare in the feces of premature 
infants unless supplemented in the form of probiotics(19). In these infants, bifidobacteria 
and Bacteroidetes were present in very limited amounts confirming previous observations of 
the marked differences in the fecal microbiota between term and preterm infants(20). 
Bifidobacteria are associated with improved growth and vaccine responsiveness in term 
breast-fed infants in a developing country(21). In premature infants, administration of 
probiotics containing bifidobacteria leads to a decreased risk of NEC, a common and 
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devastating inflammatory disease of neonates(22, 23). In animal models and in vitro, 
bifidobacteria decrease inflammation and gut permeability(24, 25). In this small group of 
premature infants (none of whom received probiotic organisms), the numbers of 
bifidobacteria were low (< 1% of all bacteria).
Enterobacteriaceae (phylum Proteobacteria) include pathogens that are associated with NEC 
and sepsis in premature infants such as E. coli, Klebsiella, Enterobacter, Proteus, and 
Serratia. These organisms are rare in the healthy adult gut, but common and often dominant 
in the intestine of premature infants. Colonization with Klebsiella in the first week of 
life(26) and with Enterobacteriaceae in the second week of life(27) have both been 
associated with increased risk of later development of NEC (which generally presents at 2–6 
weeks of age). A bloom of these organisms has been demonstrated just prior to the onset of 
NEC in premature infants(28). Some of these bacteria are capable of inducing an 
inflammatory response in the host and then utilizing the products of inflammation to 
outcompete other intestinal bacteria(29, 30). The associations noted in these premature 
infants suggest that specific HMOs in human milk may decrease intestinal 
Enterobacteriaceae (e.g. fucosylated HMOs such as LDFT and LNFP V and structures that 
are both fucosylated and sialylated) while other HMOs in the milk are associated with 
increased intestinal Enterobacteriaceae (e.g. LNnH, 5031a and HMOs that contain neither 
fucose nor sialic acid). The mechanisms underlying these associations likely include both 
the host and interactions with other gut microbes as Enterobacteriaceae are unable to utilize 
HMOs as a food source(31).
The impact of host secretor status on susceptibility to various infections is well documented 
and somewhat balanced in the adult population such that both secretors and non-secretors 
have differing advantages against specific pathogens. Recent demonstration of rapid 
fucosylation of glycans on the luminal surface of the enterocyte in response to stimulation of 
Toll-like receptors 2, 4, and 9 suggest this response (possible only in the secretor individual) 
may be important in protecting and nourishing gut commensals in the midst of infection(32). 
In the premature infant, the inability of the non-secretor mother to provide key fucosylated 
HMOs appears to significantly influence the developing microbiota. The capacity of gut 
microbes to deconstruct specific linkages is a second promising mechanism underlying the 
observed associations. Recent studies have demonstrated marked differences between 
bacterial species in the capacity to consume specific HMOs(4) and marked differences at the 
species level in production of specific glycosidases(33).
Dysbiosis is often defined as alterations in the richness and diversity of the microbiota or 
more recently as delayed maturation of the microbiota of the infant(34). While increased 
diversity of the microbiota may be beneficial in the adult, limited data suggest that prior to 
weaning a less complex microbiota that is dominated by bifidobacteria is associated with 
improved health (e.g. growth, thymus size, and vaccine response)(21). Dysbiosis as a 
potentially alterable risk factor for NEC is based on several observations: increased risk of 
NEC with increased exposure to antibiotics(35) and acid suppressing agents(36) (both 
associated with dysbiosis), decreased risk of NEC with human milk(10) and probiotics(22) 
(both associated with less severe dysbiosis), and from direct observations(26). While human 
milk decreases the risk of NEC, it appears to have less of an impact on the microbiota of the 
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premature infant than other factors such as antibiotic exposure and environmental factors(20, 
37).
The observed differences in absorption of specific HMO structures is consistent with 
previous observations(7) and with the recent reports of HMOs in the plasma(6, 38). Further 
exploration of this area is needed to determine any effects of HMO in the systemic 
circulation and/or urinary tract. In addition, if these differences are consistent it may be 
possible to develop ratios of urine:fecal HMOs as a marker of gut permeability for the infant 
(similar to the lactulose:mannitol test in current use for children and adults).
The number of mother-infant dyads included in this study is too small to make any firm 
conclusions, but is reasonable to generate hypotheses for testing in future larger studies. 
Perhaps the most compelling hypotheses generated by these data include the following: 1) 
that human milk rich in fucosylated HMOs is protective against dysbiosis while human milk 
rich in HMOs without fucose or sialic acid increases the risk of dysbiosis, 2) that milk from 
non-secretor mothers may not be as protective against dysbiosis and NEC as milk from 
secretor mothers (this hypothesis is consistent with observations of increased sepsis and 
NEC in non-secretor babies who likely have non-secretor mothers(15)) and 3) that 
premature infant fecal HMO composition is a biomarker, with feces high in HMOs 
containing sialic acid (e.g. 3’SL) and HMOs with neither fucose nor sialic acid associated 
with dysbiosis and feces high in fucosylated HMOs (particularly LDFT) associated with less 
severe dysbiosis. Given the observation that fucosylation is an immature and inconsistent 
process in the mammary gland of the mother delivering prematurely, these data also suggest 
the hypothesis that premature infants may benefit from supplementation with fucosylated 
HMOs (e.g. through pooled donor human milk). Future studies to confirm these 
observations and to correlate milk HMO composition and fecal HMO composition with 
short term outcomes (e.g. NEC and sepsis) and long-term outcomes (e.g. growth and 
neurodevelopmental outcomes) would be valuable.
Materials and Methods
We collected specimens of stool and urine from 14 premature infants enrolled in a clinical 
trial of prebiotic supplementation(17) and milk from their mothers. The study was approved 
by the Institutional Review Board of the University of California Davis, informed consent 
was obtained prior to enrollment and the study was registered at clinicaltrials.gov 
(NCT00810160). Mean gestational age was 27 weeks at birth and 30 weeks at the time of 
enrollment. All infants were receiving enteral feedings of at least 100 ml/kg/d. Specimens 
described in this paper were obtained at baseline (prior to initiation of any supplement) from 
infants receiving exclusively their mother’s own milk (no donor human milk). Specimens 
were frozen at −40° C upon collection and transported on dry ice for analysis. Extraction 
and analysis of HMOs in milk, urine and feces was performed as previously described(7). 
The non-parametric Mann Whitney Rank Sum test was used to compare abundance of 
specific HMO structures in urine and stool and linear regression was used to correlate HMO 
abundance and fecal microbial abundance. As this study is predominantly a hypothesis 
generating exercise we reported all p values <0.1.
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Bacterial DNA was extracted from the stool specimens as described in the clinical trial(17), 
however in addition to the analyses by polymerase chain reaction and terminal restriction 
fragment length polymorphism (TRFLP) previously presented, the samples were analyzed 
by next generation sequencing for this paper. For these analyses, DNA library construction 
was carried out as previously described (39) and submitted to the UC Davis Genome Center 
DNA Technologies Core for sequencing on an Illumina MiSeq instrument (Illumina, San 
Diego CA). QIIME software package (University of Colorado. Boulder CO, version1.7.0) 
was used for quality filtering and demultiplexing the resulting sequencing data(40). OTUs 
were assigned using UCLUST (drive5.com, Tiburon, CA) based on 97% pairwise 
identity(41) and taxonomic classification was based on the Ribosomal Database Project 
classifier (Michigan State University, East Lansing, MI) against a representative subset of 
the Greengenes 16S rRNA database (Second Genome, South San Francisco, CA, 
gg_otus_12_10 release)(42, 43). Taxonomic relative abundance data from the QIIME data 
analysis was used to calculate correlations between HMO consumption and fecal bacteria 
abundance.
To visualize correlations between HMO consumption and fecal bacteria, custom R scripts 
were developed. HMO or bacterial populations with a maximum abundance less than 0.02 
were removed from further analysis. A Spearman’s correlation matrix was computed using 
the remaining HMO and bacteria features. The procedure was repeated at the phylum, order, 
and genus levels. We chose to use the Spearman's correlation because it is a nonparametric 
measure that is robust to outliers and does not require that the data be normally distributed.
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Figure 1. 
Relative abundance of groups of HMOs in the milk, urine, and feces for each of the 14 
mother-infant dyads. White: fucosylated HMOs, black: sialylated HMOs, grey: fucosylated 
and sialylated HMOs, hatched: HMOs with neither fucose nor sialic acid. Panels A=patient 
4, B=patient 6, C=patient 9, D=patient 10, E=patient 13, F=patient 14, G=patient 16, 
H=patient 18, I=patient 20, J=patient 21, K=patient 22, L=patient 26, M=patient 27, 
N=patient 30. M=milk, F=feces, U=urine, NA=specimen not available.
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Figure 2. 
Composition of the fecal microbiota determined by Next Generation Sequencing in twelve 
of the infants (6 with secretor mothers and 6 with non-secretor mothers). A. Phylum level, 
White: Actinobacteria, black: Bacteroidetes, grey: Firmicutes, hatched: Proteobacteria. B 
Order level. White: Bifidobacteriales, black: Bacteroidales, grey: Bacillales, hatched: 
Lactobacillales, dots: Clostridiales, light grey: Enterobacteriales, double hatched: 
Pseudomonadales, vertical stripes: others.
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Figure 3. 
Linear regression associations between groups of milk HMOs and fecal microbes by phylum 
(n=12). A. R2=0.63, p=0.002. B. R2=0.31, p=0.06. C. R2=0.36, p=0.04. D. R2=0.48, p=0.01. 
E. R2=0.42, p=0.02.
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Figure 4. 
Heat map demonstrating correlations between milk HMO groups and fecal bacterial orders 
(top) and between fecal HMO groups and fecal bacterial orders (bottom). Colors represent 
strength of correlations with deep blue representing Spearman’s rho=1 and deep red 
representing Spearman’s rho=−1.
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Table 1
Mean percentage of HMO structures in the milk, urine, and feces.
Structure Mass Milk (N=14), Mean% (SD) Urine (N=12), Mean% (SD) Feces (N=13), Mean% (SD)
3’FL 490.1893 0.277 (0.647) 0.761 (1.65) 0.0546 (0.0988)
2’FL 490.1908 22.0 (22.3) 8.67 (11.4) 9.22 (12.9)
LDFT 636.2476 2.63 (3.73) 5.10 (6.64) 3.06 (3.40)
LNT/LNnT 709.2654/709.2655 22.6 (17.5) 29.6 (25.0) 25.0 (17.1)
LNFP II 855.3199 1.67 (2.46) 0.779 (1.91) 4.12 (5.15)
LNFP III 855.3225 0.614 (1.22) 0.201 (0.406) 1.17 (1.99)
LNFP I 855.3233 0.764 (1.64) 4.78 (9.15) 0.767 (1.87)
LNFP V 855.3223 7.24 (9.87) 12.3 (13.9) 4.63 (9.03)
LNDFH I/LNDFH II 1001.378/1001.3813 2.47 (5.90) 1.22 (2.09) 7.04 (11.7)
LNH 1074.4017 3.73 (2.77) 1.90 (3.16) 2.03 (1.55)
LNnH 1074.3946 2.20 (1.82) 1.75 (2.44) 1.48 (1.48)
pLNH 1074.3957 1.47 (1.79) 0.445 (0.497) 1.48 (1.99)
A-hepta 1204.468 0 (0) 0.0193 (0.0670) 0.116 (0.410)
6 structuresa 1220.455-1220.474 4.45 (4.12) 6.45 (7.63) 6.13 (3.41)
4 structuresb 1366.510-1366.522 2.42 (3.09) 3.30 (4.80) 3.53 (2.34)
TFLNH 1512.576 0.210 (0.233) 0.138 (0.265) 0.424 (0.517)
5130a 1585.583 0.566 (0.817) 0.0113 (0.0392) 0.611 (0.832)
5130b 1585.585 0.112 (0.173) 0.326 (0.417) 0.478 (0.382)
5130c 1585.585 0.150 (0.262) 0.0742 (0.156) 0.289 (0.326)
F-LNO 1585.588 0.550 (0.585) 0.183 (0.431) 0.338 (0.356)
6 structuresc 1731.642-1731.649 0.632 (0.757) 0.274 (0.584) 1.29 (1.00)
TFiLNO, 5330a 1877.699-1877.702 0 (0) 0 (0) 0.104 (0.260)
6140a 1950.719 0.224 (0.369) 0 (0) 0.178 (0.328)
6’SL 635.229 1.81 (2.35) 0.803 (2.78) 4.62 (6.43)
3’SL 635.227 1.01 (0.878) 4.62 (8.16) 0.865 (1.24)
6’SLN 676.254 0.0454 (0.0916) 2.31 (3.52) 0.823 (2.33)
3’SLN 676.252 0 (0) 1.68 (4.16) 0.00230 (0.00827)
3’Sle 822.314 0 (0) 0.085 (0.116) 0 (0)
LSTa/b/c 1000.362-1000.365 11.0 (10.8) 6.35 (5.39) 11.8 (12.2)
F-LSTc 1146.419 1.35 (2.08) 0.0654 (0.150) 1.36 (2.24)
DSLNT 1291.446 0.239 (0.457) 0.412 (0.543) 0.242 (0.618)
S-LNH 1365.495 0.490 (0.725) 0.484 (0.449) 0.296 (0.368)
4021a 1365.494 0.715 (0.980) 0.570 (1.97) 0.768 (0.979)
S-LNnH II 1365.494 1.97 (2.16) 0.962 (1.53) 1.08 (1.22)
4021b 1365.491 0.221 (0.287) 0.151 (0.284) 0.166 (0.213)
7 structuresd 1511.547-1511.554 3.13 (2.27) 2.68 (2.73) 3.38 (2.71)
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Structure Mass Milk (N=14), Mean% (SD) Urine (N=12), Mean% (SD) Feces (N=13), Mean% (SD)
DFS-LNH 1657.612 0.234 (0.214) 0.183 (0.279) 0.190 (0.295)
5031a 1730.622 0.203 (0.251) 0.113 (0.188) 0.230 (0.268)
FS-LNO/5131a 1876.682 0.108 (0.142) 0.0456 (0.745) 0.259 (0.368)
6041a 2095.76 0.0455 (0.0703) 0 (0) 0.0996 (0.179)
The structures underlined and highlighted in bold are found in milk and are more than 5 fold more abundant in urine than feces. The structures 
underlined and in italics are found in milk and are more than 5 fold more abundant in feces than urine.
The following structures were detectable in at least one specimen of milk, urine and feces with a mean of less than 0.1%: 4320a, Tetra-iso-LNO
The following structures were not detected in any milk or urine samples, but were detected in at least one fecal sample at a mean of less than 0.1%: 
6340a, 6340b, 6340c, 6440a, 5231a, 5231b, 5331a.
The following structure was not detected in any urine samples, but was detected in at least one milk and and one fecal sample at a mean of less than 
0.1%: 6240a
a
MFpLNH IV, 4120a, MFLNH III, MFLNH I, IFLNH III, and IFLNH I
b
DFpLNH II, DFLNHb, DFLNHa, DFLNHc
c
DFLNO I, DFLNnO II, 5230a, DFLNnO I, DFLNO II, 5230b
d4121a, 4121b, FS-LNH III, FS-LNH, FS-LNH I, FS-LNnH I, FS-LNH II
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Table 2
Mean percentages of groups of HMOs in milk, urine and feces.
Structure Milk (N=14), Mean% (SD) Urine (N=12), Mean% (SD) Feces (N=13), Mean% (SD)
Fucose + Sialic acid 4.91 (3.81) 3.26 (3.32) 5.60 (5.52)
Fucose 46.9 (24.0) 40.3 (21.4) 41.5 (22.9)
Sialic acid 17.0 (13.6) 20.1 (13.0) 19.8 (20.2)
No Fucose or Sialic acid 31.2 (16.9) 36.3 (24.5) 33.1 (20.1)
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Table 4
Associations between milk HMOs and fecal bacterial phyla.
Milk HMO Fecal Bacteria Correlation R-squared P value
2’FL Proteobacteria negative 0.27 0.09
LDFT Proteobacteria negative 0.42 0.02
LNFP V Proteobacteria negative 0.37 0.04
LNnH Proteobacteria positive 0.37 0.04
5031a Proteobacteria positive 0.35 0.04
2’FL Firmicutes positive 0.40 0.03
LDFT Firmicutes positive 0.56 0.005
LNFP V Firmicutes positive 0.51 0.009
LNH Firmicutes negative 0.34 0.05
LNnH Firmicutes negative 0.34 0.05
4120 (six structures) Firmicutes negative 0.25 0.09
TFLNH Firmicutes positive 0.29 0.07
3’SL Firmicutes negative 0.28 0.08
5031a Firmicutes negative 0.32 0.05
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Table 5
Associations between fecal HMOs and fecal bacterial phyla.
Fecal HMO Fecal bacteria Correlation R-squared P value
LDFT Proteobacteria negative 0.40 0.03
LNH Proteobacteria positive 0.35 0.04
4120 (six structures) Proteobacteria positive 0.41 0.03
5130a Proteobacteria positive 0.63 0.002
5230 (five structures) Proteobacteria positive 0.45 0.02
6140a Proteobacteria positive 0.25 0.098
3’SL Proteobacteria positive 0.29 0.07
5031a Proteobacteria positive 0.27 0.08
6041a Proteobacteria positive 0.36 0.04
LDFT Firmicutes positive 0.55 0.006
4120 (six structures) Firmicutes negative 0.26 0.09
5130a Firmicutes negative 0.58 0.004
5230 (five structures) Firmicutes negative 0.36 0.04
6140a Firmicutes negative 0.25 0.099
6041a Firmicutes negative 0.31 0.06
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Table 6
Associations between urine HMOs and fecal bacterial phyla.
Urine HMO Fecal bacteria Correlation R-squared P value
Sialylated HMOs Proteobacteria positive 0.35 0.05
p-LNH Proteobacteria positive 0.34 0.06
5130b Proteobacteria positive 0.30 0.08
3’Sle Proteobacteria positive 0.29 0.09
Sialylated HMOs Firmicutes negative 0.39 0.04
2’FL Firmicutes positive 0.33 0.07
p-LNH Firmicutes negative 0.35 0.05
5130b Firmicutes negative 0.31 0.08
3’Sle Firmicutes negative 0.28 0.09
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